• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Gastrointestinal Cancer Research : GCR >Chemotherapy for Advanced Gastric Cancer: Review of Global and Japanese Status
【2h】

Chemotherapy for Advanced Gastric Cancer: Review of Global and Japanese Status

机译：晚期胃癌的化学疗法：全球和日本现状的回顾

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gastric cancer is the second most common cause of cancer death in the world. In Japan, it is the most commonly diagnosed cancer and the second leading cause of cancer death. Standard treatment for advanced gastric cancer has not been established and prognosis remains poor worldwide. Numerous phase II studies have demonstrated promising results in overall response rate for new agents such as docetaxel, irinotecan, oxaliplatin, capecitabine, and S-1; some of these new agents may have improved toxicity profiles. Dozens of hase III studies comparing chemotherapy regimens have been conducted globally, several of which are ongoing in Japan. Results will be available in the near future. However, potential gains seem limited with the new regimens: a less than 1- to 2-month improvement in survival and a 10% or less improvement in response rate. This article reviews the history of, and recent progress in, chemotherapy for advanced gastric cancer globally, with a detailed look at investigations in Japan.
机译：胃癌是世界上第二大最常见的癌症死亡原因。在日本，它是最常被诊断的癌症，也是癌症死亡的第二大主要原因。晚期胃癌的标准治疗方法尚未建立，全世界的预后仍然很差。大量的II期研究表明，多西他赛，伊立替康，奥沙利铂，卡培他滨和S-1等新药的总体缓解率令人鼓舞。这些新药中的某些可能具有改善的毒性特征。全球已经进行了数十项比较化疗方案的hase III研究，其中一些正在日本进行。结果将在不久的将来提供。但是，新疗法的潜在获益似乎有限：生存期不到1到2个月的改善和缓解率的10％或更少的改善。本文详细回顾了日本的研究情况，回顾了全球晚期胃癌化疗的历史和最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号